Through various mechanisms, including inhibiting FasL- and LIGHT-mediated cell death and promoting tumor cell inflammation and migration, DcR3 has been implicated in cancer progression across different types of malignancies [28–34]. This evidence concerns the gene TNFRSF6B and cancer.